secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2025-11-19T23:59:59+00:00
Accession:  0001193125-25-286642
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics licenses HCW11-006 to Trimmune; $7M upfront (half cash, half equity)
--------------------------------------------------------------------------------

- Amended License, Research & Co-Development Agreement with Beijing Trimmune for HCW11-006 in vivo applications.
- $7.0M upfront fee: $3.5M cash at closing, $3.5M in Trimmune equity.
- Company retains payment-free option to recapture rights for US, Canada, Central & South America after Phase 1.
- Trimmune responsible for all R&D, manufacturing, clinical, regulatory, commercialization costs in its territory.
- If closing not completed by Jan 16, 2026, all IP and rights to HCW11-006 return to HCW.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000119312525286642/0001193125-25-286642-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000119312525286642/hcwb-20251117.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-286642

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer